From tailor-made to ready-to-wear meningococcal B vaccines: Longitudinal study of a clonal meningococcal B outbreak

The Lancet Infectious Diseases

Volumn 11, Issue 6, 2011, Pages 455-463

  Caron, François ^a   Du Châtelet, Isabelle Parent ^b   Leroy, Jean Philippe ^a,e   Ruckly, Corinne ^c   Blanchard, Myriam ^d   Bohic, Nicole ^e   Massy, Nathalie ^a   Morer, Isabelle ^f   Floret, Daniel ^g   Delbos, Valérie ^a   Hong, Eva ^c   Révillion, Martin ^d   Berthelot, Gilles ^h   Lemée, Ludovic ^a   Deghmane, Ala Eddine ^c   Bénichou, Jacques ^a   Lévy Bruhl, Daniel ^b   Taha, Muhamed Kheir ^c  

^a UNIVERSITÉ DE ROUEN   (France)

^b INSTITUT DE VEILLE SANITAIRE   (France)

^c INSTITUT PASTEUR   (France)

^d Cellule Interrégionale d'Epidémiologie   (France)

^e Agence Régionale de Santé   (France)

^f AFSSAPS   (France)

^g Comité Technique des Vaccinations ^*  (France)

^h Centre Hospitalier De Dieppe   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CHILD; DRUG SAFETY; EPIDEMIC; FRANCE; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION;

ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE OUTBREAKS; FRANCE; HUMANS; INCIDENCE; INFANT; LONGITUDINAL STUDIES; MASS VACCINATION; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; POISSON DISTRIBUTION;

EID: 79956274391     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70027-5     Document Type: Article

References (37)

1. Stephens DS, Greenwood B, Brandtzaeg P Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
2. Annual epidemiological report on communicable diseases in Europe 2009 2009, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, Stockholm, (accessed March 28, 2011). http://ecdc.europa.eu/en/publications/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf.
3. Cartwright KA Meningococcal carriage and disease. Meningococcal disease 1995, 115-146. John Wiley & Sons, Chichester. K.A. Cartwright (Ed.).
4. Cruz C, Pavez G, Aguilar E, et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect 1990, 105:119-126.
5. Lystad A, Aasen S The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann 1991, 14:57-65.
6. Poolman JT, Jónsdóttir K, Jones DM, Lind I, Froholm LO, Zanen HC Meningococcal serotypes and serogroup B disease in north-west Europe. Lancet 1986, 2:555-558.
7. Weihe P, Mathiassen B, Rasmussen JM, Petersen T, Isager H An epidemic outbreak of group B meningococcal disease on the Faroe Islands. Scand J Infect Dis 1988, 20:291-296.
8. Parent du Châtelet I, Taha MK, Lepoutre A, Deghmane A, Maine C, Levy-Bruhl D Invasive meningococal disease in France, 2008. Bull Epidemiol Hebd 2009, 46-47:489-493. (accessed March 28, 2011). http://www.invs.sante.fr/beh/2009/46_47/beh_46_47_2009.pdf.
9. Rouaud P, Perrocheau A, Taha MK, et al. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveill 2006, 11:178-181.
10. Feavers IM, Pizza M Meningococcal protein antigens and vaccines. Vaccine 2009, 27(suppl 2):B42-B50.
11. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
12. Giuliani MM, du-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103:10834-10839.
13. Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338:1093-1096.
14. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(suppl 2):B3-12.
15. Milagres LG, Gorla MC, Sacchi CT, Rodrigues MM Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 1998, 66:4755-4761.
16. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281:1520-1527.
17. Bjune G, Gronnesby JK, Hoiby EA, Closs O, Nokleby H Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann 1991, 14:125-130. discussion 130-32.
18. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38:413-418.
19. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007, 26:345-350.
20. Wong SH, Lennon DR, Jackson CM, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009, 28:385-390.
21. Taha MK, Zarantonelli ML, Alonso JM, et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007, 25:2537-2538.
22. Perrocheau A, Bonmarin I, Levy-Bruhl D Invasive meningococal disease in France, 2002. Bull Epidemiol Hebd 2003, 43-47:209-212. (accessed March 28 2011). http://www.invs.sante.fr/beh/2003/43/beh_43_2003.pdf.
23. Taha MK, Giorgini D, Ducos-Galand M, Alonso JM Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 2004, 42:4158-4163.
24. Feiring B, Fuglesang J, Oster P, et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006, 13:790-796.
25. Holst J, Feiring B, Naess LM, et al. The concept of " tailor-made" , protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23:2202-2205.
26. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007, 25:3080-3084.
27. Rosenqvist E, Hoiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995, 63:4642-4652.
28. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21:734-737.
29. Bégaud B, Evreux JC, Jouglard J, Lagier J Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 1985, 40:111-118.
30. Katz LH, Zelazny A, Scharf S, et al. Mass antibiotic treatment to stop an outbreak of meningococcal disease: a molecular analysis. Clin Microbiol Infect 2007, 13:943-946.
31. Shehab S, Keller N, Barkay A, Leitner L, Leventhal A, Block C Failure of mass antibiotic prophylaxis to control a prolonged outbreak of meningococcal disease in an Israeli village. Eur J Clin Microbiol Infect Dis 1998, 17:749-753.
32. Loring BJ, Turner N, Petousis-Harris H MeNZB vaccine and epidemic control: when do you stop vaccinating?. Vaccine 2008, 26:5899-5904.
33. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009, 49:597-605.
34. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13:821-829.
35. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992, 340:1074-1078.
36. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000, 38:3323-3328.
37. Invasive Neisseria meningitidis in Europe 2006 2006, European Union Invasive Bacterial Infections Surveillance Network, Health Protection Agency, London, (accessed March 28, 2011). http://www.hpa-bioinformatics.org.uk/euibis/documents/2006_meningo.pdf.